Veracyte (VCYT) Stock
Genomic diagnostics company reducing unnecessary medical procedures. Here's the price, business snapshot, and what's worth knowing about Veracyte in October 2026.
Veracyte, Inc. (VCYT) is a diagnostics company focused on genomic and molecular tests that help clinicians make more informed decisions in cancer and other disease pathways. Its test portfolio — including widely cited thyroid and lung classifiers and a prostate genomic tool — aims to reduce unnecessary procedures by improving diagnostic accuracy. Revenue comes largely from test sales, reimbursement from insurers and continued clinical validation. Key growth drivers are wider clinical adoption, expanded indications, and international coverage, while risks include reimbursement changes, competitive innovation, and regulatory or clinical trial setbacks. The company operates in a sector where scale, data and clinician trust matter, and growth often requires heavy investment in R&D and sales infrastructure. This summary is educational and not personalised financial advice — investors should review the latest financial statements and consider their own risk tolerance before acting, as past performance offers no guarantee of future returns.
Veracyte (VCYT) Stock Forecast
Analyst price target, next 12 months
$51.80
+13.1% vs today's $45.81
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Veracyte have a consensus 12-month target of $51.80, above the current price of $45.81.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts highly recommend buying Veracyte's stock, expecting it to rise significantly in value.
Financial Health
Veracyte Inc. is performing well with strong revenue, profit margins, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Adoption and Revenue
Expanded clinician uptake and broader insurance coverage can drive revenue, though reimbursement shifts may affect results.
International Expansion
Growing presence outside the US can open new markets, but local regulation and payer systems add complexity.
Data and Innovation
Proprietary genomic data and continued R&D can support differentiation, though competitors and tech change pose risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
